Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

Rojas Laimito, Katerin; Trilla Fuertes, Lucía; Gámez Pozo, Angelo; Chiva, Cristina; Sepúlveda, Juan M.; Manso, Luis; Prado Vázquez, Guillermo; Zapater-Moros, Andrea; López Vacas, Rocío; Ferrer-Gómez, María; Mendiola, César; Espinosa Arranz, Enrique; Sabidó Aguadé, Eduard, 1981-; Ciruelos, Eva; Fresno Vara, Juan Ángel

doi:http://dx.doi.org/10.3332/ecancer.2019.891

Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer

License

Citation

Rojas LK, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L et al. Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer. Ecancermedicalscience. 2019;13:891. DOI: 10.3332/ecancer.2019.891

Abstract

Background: Breast cancer (BC) is the most frequent tumour in women. Triple negative tumours (TNBC)–which are associated with minor survival rates—lack markers predictive of response to anticancer drugs. Triple negative tumours frequently metastasise to the central nervous system (CNS). Objective: The main objective of this study was to study differences in tumour protein expression between patients with CNS metastases and those without this kind of spread, and propose new biomarkers. Methods: A retrospective study was performed. Targeted proteomics and statistical analyses were used to identify possible biomarkers. Results: Proteins were quantified by a targeted proteomics approach and protein expression data were successfully obtained from 51 triple negative formalin-fixed paraffin-embedded samples. ISG15, THBS1 and AP1M1 were identified as possible biomarkers related with CNS metastasis development. Conclusions: Three possible biomarkers associated with CNS metastases in TNBC tumours were identified: ISG15, THBS1 and AP1M1. They may become markers predicting the appearance of CNS infiltration in triple negative BC.